NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

連續性腎替代性治療 (CRRT)的全球市場 (∼2026年):各產品 (拋棄式品 (血液過濾器、輸液套組)、機器、透析液、補充液)、模式 (SCUF、CVVH、CVVHD、CVVHDF)、患者層 (成人、兒童、新生兒)、地區

Continuous Renal Replacement Therapy (CRRT) Market by Product (Disposables (Hemofilters, Bloodlines), Machine, Dialysates, Renal Replacement fluids), Modality (SCUF, CVVH, CVVHD, CVVHDF), Patient (Adult, Pediatrics, Neonates) - Global Forecasts to 2026

出版商 MarketsandMarkets 商品編碼 1016545
出版日期 內容資訊 英文 176 Pages
訂單完成後即時交付
價格
連續性腎替代性治療 (CRRT)的全球市場 (∼2026年):各產品 (拋棄式品 (血液過濾器、輸液套組)、機器、透析液、補充液)、模式 (SCUF、CVVH、CVVHD、CVVHDF)、患者層 (成人、兒童、新生兒)、地區 Continuous Renal Replacement Therapy (CRRT) Market by Product (Disposables (Hemofilters, Bloodlines), Machine, Dialysates, Renal Replacement fluids), Modality (SCUF, CVVH, CVVHD, CVVHDF), Patient (Adult, Pediatrics, Neonates) - Global Forecasts to 2026
出版日期: 2021年06月22日內容資訊: 英文 176 Pages
簡介

全球連續性腎替代性治療 (CRRT)的市場規模在預測期間內預計以7.3%的年複合成長率發展,從2021年的12億美元,成長到2026年17億美元的規模。

AKI的發病率上升,對ICU患者而言的有效腎替代療法的重要性高漲等要素成為推動產品需求的要素。再加上各國政府提高CRRT療法的認知度的配合措施,及先進性的CRRT系統的市場投入增加,也是推動在預測期間內需求的要素。

各產品中,透析液、補充液的部門在預測期間內預計佔最大的佔有率,還有顯示最大的成長率。還有各種模式中,CVVHDF (持續性靜脈血液過濾透析)部門預計顯示最大的成長。

本報告提供全球連續性腎替代性治療 (CRRT)的市場調查,市場定義和概要,價值鏈,新型冠狀病毒感染疾病 (COVID-19) 以及其他的市場影響因素分析,法律規章、償付環境,市場規模的變化、預測,產品、模式、年齡層、地區等各種區分的明細,競爭環境,主要企業簡介等彙整資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

第5章 市場概要

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 課題
  • 法規情形
  • 償付方案
  • COVID-19的影響
  • 價值鏈
  • 生態系統
  • 價格趨勢分析
  • 波特的五力分析

第6章 市場分析、預測:各產品

  • 透析液、補充液
  • 拋棄式品
    • 血液過濾器
    • 輸液套組、管
    • 其他
  • CRRT系統

第7章 市場分析、預測:各種模式

  • CVVH (持續性靜脈血液過濾
  • CVVHDF (持續性靜脈血液過濾透析)
  • CVVHD (持續性靜脈血液透析機)
  • SCUF (持續的徐緩除水)

第8章 市場分析、預測:各年齡層

  • 成人
  • 兒童、新生兒

第9章 市場分析、預測:各地區、主要國家

  • 歐洲
  • 北美
  • 亞太地區
  • 南美
  • 中東、非洲

第10章 競爭情形

  • 概要
  • 主要企業的策略
  • 龍頭企業的收益佔有率分析
  • 全球市場佔有率分析
  • 競爭領導製圖
  • 新興企業/中小企業的競爭領導製圖
  • 主要企業的足跡

第11章 企業簡介

  • 主要企業
    • BAXTER INTERNATIONAL INC.
    • FRESENIUS MEDICAL CARE AG & CO. KGAA
    • NIKKISO CO., LTD.
    • B. BRAUN MELSUNGEN AG
    • MEDTRONIC PLC
    • ASAHI KASEI CORPORATION
    • TORAY MEDICAL CO., LTD.
    • NIPRO CORPORATION
    • INFOMED SA
    • MEDICA SPA
    • MEDITES PHARMA SPOL. S.R.O
    • MEDICAL COMPONENTS, INC.
    • SWS HEMODIALYSIS CARE CO. LTD.
    • NINGBO TIANYI MEDICAL DEVICES CO., LTD.
    • ANJUE MEDICAL EQUIPMENT CO., LTD.
  • 新興企業
    • KIMAL
    • JIANGXI SANXIN MEDTEC CO., LTD.
    • ALLMED MEDICAL PRODUCTS CO., LTD.
    • DIALCO MEDICAL INC.
    • BROWNDOVE HEALTHCARE PVT. LTD.

第12章 附錄

目錄
Product Code: MD 3842

The global continuous renal replacement therapymarket size is projected to reach USD 1.7billion by 2026 from USD 1.2billion in 2021, at a CAGR of 7.3% during the forecast period.Factors such as rise in the incidence of AKI and rising emphasis on effective renal replacement therapy among ICU patients are factors boosting the demand for CRRT system and disposables. Moreover, the initiatives undertaken by governments to increase the awareness about CRRT therapy along with the increase in the launch of advanced CRRT system in the market, are anticipated to boost the demand for continuous renal replacement therapy during the forecast period.

The recent COVID-19 global pandemic has also impacted thecontinuous renal replacement therapy market. The surge in the number of COVID cases, along with the rise in its severity rate, is likely to create a potential increase in the incidence of kidney damage. This makes AKI the next emerging healthcare concern after respiratory tract infections among patients with COVID-19.Due to the pandemic, the demand for renal replacement fluids has increased significantly worldwide. The demand for RRT among patients with COVID-19 has increased fivefold in comparison to the historical US populations (4.9% as of 2020 VS. 0.9% earlier) (Source: American Society of Nephrology, 2021). According to an article published by the International Society of Nephrology 2020, countries such as China and Italy reported AKI rates as high as 29%. The early initiation of continuous renal replacement therapy (CRRT) is an important step to curbing the rising incidence of AKI due to the COVID-19 infection. However, owing to the rapid rise in the demand by healthcare systems, HD and PD exist as an alternative dialysis treatment in ICUs, which can have a negative impact on the growth of the CRRT market during this period.

"The dialysate and replacement fluid segmentto capture the largest share in continuous renal replacement therapymarket, by product, during the forecast period."

Thedialysate and replacement fluidsegment is expected to witness the highest growth rate during the forecast period. The high growth in this owes to the significant rise in demand for CRRT in the treatment of hemodynamically unstable patients, the increased number of manufacturers offering dialysate and replacement fluids for renal replacement therapy, and the strong presence of players in the market.

"The CVVHDF segment to witness highest growth rate in continuous renal replacement therapy market, by modality in 2021."

The CVVHDF modality segment is anticipated to witness the highest growth rate during the forecast period. The growing preference of CVVHDF modality among a nephrologist and critical care physician, and the advantages such as better clearance of medium-sized solutes as compared to hemodialysis (owing to the combination of hemofiltration with the continuous HD procedure), proper acid-base balance without additional intervention, and a significant reduction in CRRT-related phosphate depletion area likely to play strong role in supporting the growth of the segment in the coming years.

"The Adultssegment accounted for the largest share of thecontinuous renal replacement therapy, by age group, in 2021"

The rapidly growing cases of adult acute renal disease injury across the globe and the rising number of hospital admission among youth adults are playing a critical role in increasing the adoption of CRRT among adult age group population. Moreover,increasing frequency of aggressive surgical and medical interventions among adults, and the increasing the risk of developing AKI and further contributing to the market growth.

"The Asia Pacific market to grow at the highest CAGR during the forecast period."

The continuous renal replacement therapymarket is segmented into five major regions, namely, North America, Europe, AsiaPacific, Latin America, and Middle East & Africa.Increase in the awareness of continuous renal replacement therapy, increasing healthcare expenditures, increasing patient population, rising sepsis incidence, increasing prevalence of hypertension & diabetes (major causes of AKI), the high use of CRRT in Australia and Japan, improving healthcare expenditure on renal diseases, and increasing accessibility to CRRT for AKI treatment.

Breakdown of supply-side primary interviews:

  • By Company Type:Tier 1: 25%, Tier 2: 30%, and Tier 3: 45%
  • By Designation:C-level: 26%, D-level: 30%, and Others: 44%
  • By Region:North America: 40.4%, Europe: 28.0%, APAC: 19.0%, Latin America: 7.7%, and the Middle East & Africa: 5.0%

The major players operatinginthe continuous renal replacement therapymarket are Baxter International Inc. (US), Fresenius Medical Care AG & Co. KGaA (Germany), NIKKISO CO., LTD. (Japan), B. Braun Melsungen AG (Germany), Asahi Kasei Corporation (Japan), Toray Medical Co., Ltd. (Japan), Infomed SA (Switzerland),Medtronic plc (Ireland), Medica S.p.A. (Italy), Medical Components, Inc. (US), Medites Pharma spol. s.r.o. (Czech Republic), SWS Hemodialysis Care Co., Ltd. (China), Ningbo Tianyi Medical Devices Co., Ltd. (China),Nipro Corporation (Japan), and Anjue Medical Equipment Co., Ltd. (China),

Research Coverage

This report studies the continuous renal replacement therapymarket based on the product, modality, age group and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions(and the respective countries in these regions).

Key Benefits of Buying the Report

This report focuses on various levels of analysis-industry trends, marketshareof top players, and company profiles, which together formbasic views and analyze the competitive landscape, emerging segments of the continuous renal replacement therapymarket, and high-growth regions and their drivers, restraints, opportunities, and challenges.The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the marketandgarner greater market shares.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY USED FOR THE STUDY
  • 1.5 MAJOR MARKET STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 BREAKDOWN OF PRIMARIES: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
    • 2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
    • 2.2.2 USAGE-BASED MARKET ESTIMATION
    • FIGURE 4 ESTIMATION OF CRRT PROCEDURES
    • FIGURE 5 MARKET SIZE ESTIMATION: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET BASED ON PRODUCT UTILIZATION METHODOLOGY
    • FIGURE 6 MARKET SIZE ESTIMATION: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET BASED ON REVENUE MAPPING METHODOLOGY
    • 2.2.3 PRIMARY RESEARCH VALIDATION
  • 2.3 DATA TRIANGULATION
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • 2.4 RESEARCH ASSUMPTIONS
  • 2.5 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

    • FIGURE 8 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
    • FIGURE 9 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021 VS. 2026 (USD MILLION)
    • FIGURE 10 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021 VS. 2026 (USD MILLION)
    • FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET

4 PREMIUM INSIGHTS

  • 4.1 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET OVERVIEW
    • FIGURE 12 RISING PREVALENCE OF AKI AND GROWING AWARENESS ABOUT CRRT TO DRIVE MARKET GROWTH
  • 4.2 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SHARE, BY AGE GROUP, 2021
    • FIGURE 13 ADULTS SEGMENT TO DOMINATE THE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET IN 2021
  • 4.3 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT AND COUNTRY
    • FIGURE 14 DIALYSATES AND REPLACEMENT FLUIDS ACCOUNT FOR THE LARGEST SHARE OF THE CRRT PRODUCTS MARKET IN THE APAC
    • FIGURE 15 APAC MARKET TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (2021-2026)

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 16 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing incidence of acute kidney injury (AKI)
    • FIGURE 17 GLOBAL INCIDENCE OF AKI, 2010 VS. 2015 VS. 2020
    • TABLE 1 NUMBER OF PEOPLE AGED 65 YEARS OR OVER, BY REGION, 2019 VS. 2050
      • 5.2.1.2 Growing number of ICU patients with AKI and increasing incidence of sepsis
    • FIGURE 18 IMPACT OF ICU-ACQUIRED AKI IN THE US
      • 5.2.1.3 Increasing clinical advantage of CRRT over intermittent blood purification
      • 5.2.1.4 Technological advancements and new product launches
      • 5.2.1.5 Growing prevalence of diabetes and hypertension
    • FIGURE 19 TOP 5 COUNTRIES WITH CHILDREN AND ADOLESCENTS WITH TYPE I DIABETES, 2019
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Stringent regulatory guidelines in North America
      • 5.2.2.2 High procedural cost of CRRT
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging markets in APAC and RoW
      • 5.2.3.2 Increasing applications of CRRT
        • 5.2.3.2.1 Evolution of CRRT from a simple renal replacement treatment to multi-organ support therapy
        • 5.2.3.2.2 Progression of CRRT from adaptive renal devices to multipurpose treatment machines
      • 5.2.3.3 Ongoing research to establish the safety and efficacy profile of CRRT
      • 5.2.3.4 Development of CRRT systems for pediatric patients
        • 5.2.3.4.1 The CARPEDIEM Project
      • 5.2.3.5 Untapped growth opportunities in North America
    • 5.2.4 CHALLENGES
      • 5.2.4.1 High complexity of CRRT
      • 5.2.4.2 Lack of standard treatment guidelines in developing nations
      • 5.2.4.3 Shortage of trained ICU professionals in developing nations
      • 5.2.4.4 Poor reimbursement scenario in developing countries
      • 5.2.4.5 Lack of awareness about the benefits of CRRT
  • 5.3 GLOBAL REGULATORY LANDSCAPE
    • 5.3.1 NORTH AMERICA
    • 5.3.2 EUROPE
    • 5.3.3 ASIA PACIFIC
      • 5.3.3.1 India
      • 5.3.3.2 China
      • 5.3.3.3 Japan
      • 5.3.3.4 South Korea
    • 5.3.4 REST OF THE WORLD (ROW)
      • 5.3.4.1 Brazil
      • 5.3.4.2 Argentina
  • 5.4 GLOBAL REIMBURSEMENT SCENARIO
    • 5.4.1 NORTH AMERICA
    • 5.4.2 EUROPE
    • 5.4.3 ASIA PACIFIC
    • 5.4.4 JAPAN
    • 5.4.5 REST OF THE WORLD (ROW)
      • 5.4.5.1 Brazil
      • 5.4.5.2 Central America and the Caribbean
  • 5.5 COVID-19 IMPACT ON THE CRRT MARKET
    • FIGURE 20 US: COVID-19 HOSPITALIZATION DATA FOR SPECIALIZED MEDICAL CONDITIONS IN ADULTS (AS OF APRIL 11, 2020)
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 21 VALUE CHAIN OF THE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
  • 5.7 ECOSYSTEM COVERAGE
  • 5.8 PRICING TREND ANALYSIS
    • TABLE 2 AVERAGE PRICE OF CRRT SYSTEMS AND CONSUMABLES, BY COUNTRY, 2020 (USD)
  • 5.9 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 3 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.9.1 THREAT FROM NEW ENTRANTS
    • FIGURE 22 THREAT FROM NEW ENTRANTS
    • 5.9.2 THREAT FROM SUBSTITUTES
    • FIGURE 23 THREAT FROM SUBSTITUTES
    • 5.9.3 BARGAINING POWER OF SUPPLIERS
    • FIGURE 24 BARGAINING POWER OF SUPPLIERS
    • 5.9.4 BARGAINING POWER OF BUYERS
    • FIGURE 25 BARGAINING POWER OF BUYERS
    • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
    • FIGURE 26 INTENSITY OF COMPETITIVE RIVALRY

6 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 4 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
  • 6.2 DIALYSATES & REPLACEMENT FLUIDS
    • 6.2.1 RISING DEMAND FOR DIALYSATES HAS SUPPORTED MARKET GROWTH
    • TABLE 5 DIALYSATES & REPLACEMENT FLUIDS MARKET, BY MODALITY, 2019-2026 (USD MILLION)
    • TABLE 6 DIALYSATES & REPLACEMENT FLUIDS MARKET, BY AGE GROUP, 2019-2026 (USD MILLION)
    • TABLE 7 DIALYSATES & REPLACEMENT FLUIDS MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 6.3 DISPOSABLES
    • TABLE 8 DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 9 DISPOSABLES MARKET, BY MODALITY, 2019-2026 (USD MILLION)
    • TABLE 10 DISPOSABLES MARKET, BY AGE GROUP, 2019-2026 (USD MILLION)
    • TABLE 11 DISPOSABLES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • 6.3.1 HEMOFILTERS
      • 6.3.1.1 Hemofilters are widely adopted during CRRT procedures for the treatment of AKI
    • TABLE 12 HEMOFILTERS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 13 HEMOFILTERS MARKET, BY MODALITY, 2019-2026 (USD MILLION)
    • TABLE 14 HEMOFILTERS MARKET, BY AGE GROUP, 2019-2026 (USD MILLION)
    • 6.3.2 BLOODLINE SETS & TUBES
      • 6.3.2.1 Established players are focusing on strengthening their bloodline sets and tubes product lines
    • TABLE 15 BLOODLINE SETS & TUBES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 16 BLOODLINE SETS & TUBES MARKET, BY MODALITY, 2019-2026 (USD MILLION)
    • TABLE 17 BLOODLINE SETS & TUBES MARKET, BY AGE GROUP, 2019-2026 (USD MILLION)
    • 6.3.3 OTHER DISPOSABLES
    • TABLE 18 OTHER DISPOSABLES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 19 OTHER DISPOSABLES MARKET, BY MODALITY, 2019-2026 (USD MILLION)
    • TABLE 20 OTHER DISPOSABLES MARKET, BY AGE GROUP, 2019-2026 (USD MILLION)
  • 6.4 CRRT SYSTEMS
    • 6.4.1 INTRODUCTION OF ADVANCED PRODUCTS TO DRIVE THE DEMAND FOR CRRT SYSTEMS
    • TABLE 21 CRRT SYSTEMS MARKET, BY MODALITY, 2019-2026 (USD MILLION)
    • TABLE 22 CRRT SYSTEMS MARKET, BY AGE GROUP, 2019-2026 (USD MILLION)
    • TABLE 23 CRRT SYSTEMS MARKET BY REGION, 2019-2026 (USD MILLION)

7 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY

  • 7.1 INTRODUCTION
    • TABLE 24 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2019-2026 (USD MILLION)
  • 7.2 CONTINUOUS VENOVENOUS HEMOFILTRATION
    • 7.2.1 WIDESPREAD ADOPTION OF CVVH IN THE TREATMENT OF ACUTE KIDNEY INJURY TO DRIVE MARKET GROWTH
    • TABLE 25 CONTINUOUS VENOVENOUS HEMOFILTRATION MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 7.3 CONTINUOUS VENOVENOUS HEMODIAFILTRATION
    • 7.3.1 CVVHDF IS USED IN PATIENTS WITH CONGESTIVE HEART FAILURE
    • TABLE 26 CONTINUOUS VENOVENOUS HEMODIAFILTRATION MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 7.4 CONTINUOUS VENOVENOUS HEMODIALYSIS
    • 7.4.1 THIS THERAPY IS MORE EFFECTIVE IN REMOVING SMALL TO MEDIUM-SIZED MOLECULES AS COMPARED TO OTHER CRRT MODALITIES
    • TABLE 27 CONTINUOUS VENOVENOUS HEMODIALYSIS MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 7.5 SLOW CONTINUOUS ULTRAFILTRATION
    • 7.5.1 SCUF DOES NOT USE DIALYSATES OR REPLACEMENT FLUIDS FOR THE REMOVAL OF EXCESS FLUID FROM THE BLOODSTREAM
    • TABLE 28 SLOW CONTINUOUS ULTRAFILTRATION MARKET, BY REGION, 2019-2026 (USD MILLION)

8 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP

  • 8.1 INTRODUCTION
    • TABLE 29 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2019-2026 (USD MILLION)
  • 8.2 ADULTS
    • 8.2.1 ADULTS HOLD THE LARGEST SHARE OF THE MARKET BY AGE GROUP
    • TABLE 30 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR ADULTS, BY REGION, 2019-2026 (USD MILLION)
  • 8.3 PEDIATRICS & NEONATES
    • 8.3.1 HIGH PREVALENCE OF AKI IN NEONATES TO AID THE MARKET GROWTH DURING THE FORECAST PERIOD
    • TABLE 31 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR PEDIATRICS & NEONATES, BY REGION, 2019-2026 (USD MILLION)

9 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION

  • 9.1 INTRODUCTION
    • TABLE 32 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 9.2 EUROPE
    • FIGURE 27 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SNAPSHOT
    • TABLE 33 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 34 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 35 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 36 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2019-2026 (USD MILLION)
    • TABLE 37 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2019-2026 (USD MILLION)
    • 9.2.1 GERMANY
      • 9.2.1.1 Germany is the largest market for continuous renal replacement therapy in Europe
    • TABLE 38 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 39 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • 9.2.2 UK
      • 9.2.2.1 Rising number of sepsis cases in the UK to support market growth
    • TABLE 40 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 41 UK: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • 9.2.3 FRANCE
      • 9.2.3.1 France is the fastest-growing market for CRRT in Europe
    • TABLE 42 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 43 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • 9.2.4 ITALY
      • 9.2.4.1 Government initiatives to promote the awareness of CRRT for renal care to drive market growth
    • TABLE 44 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 45 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION
    • 9.2.5 SPAIN
      • 9.2.5.1 Favorable reimbursement scenario to favor market growth
    • TABLE 46 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 47 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • 9.2.6 REST OF EUROPE
    • TABLE 48 ROE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 49 ROE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION)
  • 9.3 NORTH AMERICA
    • TABLE 50 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 51 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 52 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 53 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2019-2026 (USD MILLION)
    • TABLE 54 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2019-2026 (USD MILLION)
    • 9.3.1 US
      • 9.3.1.1 Large number of AKI patients in the region to drive the market growth
    • TABLE 55 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 56 US: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • 9.3.2 CANADA
      • 9.3.2.1 High cost of CRRT as compared to IHD is negatively impacting market growth in Canada
    • TABLE 57 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 58 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION)
  • 9.4 ASIA PACIFIC
    • FIGURE 28 APAC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SNAPSHOT
    • TABLE 59 APAC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 60 APAC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 61 APAC: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 62 APAC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2019-2026 (USD MILLION)
    • TABLE 63 APAC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2019-2026 (USD MILLION)
    • 9.4.1 JAPAN
      • 9.4.1.1 Increasing use of CRRT to boost the market in Japan
    • TABLE 64 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 65 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • 9.4.2 CHINA
      • 9.4.2.1 Increasing prevalence of ESRD and AKI to boost the demand for CRRT
    • TABLE 66 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 67 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • 9.4.3 INDIA
      • 9.4.3.1 Growing number of AKI patients and ICU admissions to support market growth
    • TABLE 68 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 69 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • 9.4.4 AUSTRALIA
      • 9.4.4.1 The Australian government is taking various initiatives to increase the awareness of CRRT
    • TABLE 70 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 71 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • 9.4.5 SOUTH KOREA
      • 9.4.5.1 The country is witnessing an increasing number of patients receiving CRRT for the treatment of AKI
    • TABLE 72 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 73 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • 9.4.6 REST OF ASIA PACIFIC
    • TABLE 74 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 75 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION)
  • 9.5 LATIN AMERICA
    • TABLE 76 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 77 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 78 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 79 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2019-2026 (USD MILLION)
    • TABLE 80 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2019-2026 (USD MILLION)
    • 9.5.1 BRAZIL
      • 9.5.1.1 Brazil holds the largest share in the Latin American CRRT market
    • TABLE 81 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 82 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • 9.5.2 MEXICO
      • 9.5.2.1 Large patient population and growing middle-class population to support market growth in Mexico
    • TABLE 83 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 84 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • 9.5.3 REST OF LATIN AMERICA
    • TABLE 85 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 86 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION)
  • 9.6 MIDDLE EAST & AFRICA
    • 9.6.1 LACK OF AWARENESS REGARDING CRRT TO RESTRAIN THE MARKET GROWTH IN THE REGION
    • TABLE 87 MEA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 88 MEA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 89 MEA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2019-2026 (USD MILLION)
    • TABLE 90 MEA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2019-2026 (USD MILLION)

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 KEY PLAYER STRATEGIES
  • 10.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
    • FIGURE 29 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE CRRT MARKET
  • 10.4 GLOBAL MARKET SHARE ANALYSIS (2020)
    • TABLE 91 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DEGREE OF COMPETITION
  • 10.5 COMPETITIVE LEADERSHIP MAPPING
    • 10.5.1 STARS
    • 10.5.2 EMERGING LEADERS
    • 10.5.3 PERVASIVE PLAYERS
    • 10.5.4 PARTICIPANTS
    • FIGURE 30 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
  • 10.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2020)
    • 10.6.1 PROGRESSIVE COMPANIES
    • 10.6.2 STARTING BLOCKS
    • 10.6.3 RESPONSIVE COMPANIES
    • 10.6.4 DYNAMIC COMPANIES
    • FIGURE 31 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2020
  • 10.7 FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
    • 10.7.1 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
    • TABLE 92 INDUSTRY FOOTPRINT OF COMPANIES
    • TABLE 93 REGIONAL FOOTPRINT OF COMPANIES
      • 10.7.1.1 Continuous renal replacement therapy market: Product launches and regulatory approvals (January 2018 to May 2021)
    • TABLE 94 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
      • 10.7.1.2 Continuous renal replacement therapy market: Deals (January 2018 to May 2021)
    • TABLE 95 KEY DEALS
      • 10.7.1.3 Continuous renal replacement therapy market: Other developments (January 2018 to May 2021)
    • TABLE 96 KEY OTHER DEVELOPMENTS

11 COMPANY PROFILES

  • 11.1 MAJOR PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 11.1.1 BAXTER INTERNATIONAL INC.
    • TABLE 97 BAXTER INTERNATIONAL INC.: BUSINESS OVERVIEW
    • FIGURE 32 COMPANY SNAPSHOT: BAXTER INTERNATIONAL INC.
    • TABLE 98 BAXTER INTERNATIONAL INC.: PRODUCT OFFERINGS
    • 11.1.2 FRESENIUS MEDICAL CARE AG & CO. KGAA
    • TABLE 99 FRESENIUS MEDICAL CARE AG & CO. KGAA: BUSINESS OVERVIEW
    • FIGURE 33 COMPANY SNAPSHOT: FRESENIUS MEDICAL CARE AG & CO. KGAA
    • TABLE 100 FRESENIUS MEDICAL CARE AG & CO. KGAA: PRODUCT OFFERINGS
    • 11.1.3 NIKKISO CO., LTD.
    • TABLE 101 NIKKISO CO., LTD.: BUSINESS OVERVIEW
    • FIGURE 34 COMPANY SNAPSHOT: NIKKISO CO., LTD.
    • TABLE 102 NIKKISO CO., LTD.: PRODUCT OFFERINGS
    • 11.1.4 B. BRAUN MELSUNGEN AG
    • TABLE 103 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
    • FIGURE 35 COMPANY SNAPSHOT: B. BRAUN MELSUNGEN AG
    • TABLE 104 B. BRAUN MELSUNGEN AG: PRODUCT OFFERINGS
    • 11.1.5 MEDTRONIC PLC
    • TABLE 105 MEDTRONIC PLC: BUSINESS OVERVIEW
    • FIGURE 36 COMPANY SNAPSHOT: MEDTRONIC PLC
    • TABLE 106 MEDTRONIC PLC: PRODUCT OFFERINGS
    • 11.1.6 ASAHI KASEI CORPORATION
    • TABLE 107 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW
    • FIGURE 37 COMPANY SNAPSHOT: ASAHI KASEI CORPORATION
    • TABLE 108 ASAHI KASEI CORPORATION: PRODUCT OFFERINGS
    • 11.1.7 TORAY MEDICAL CO., LTD.
    • TABLE 109 TORAY MEDICAL CO., LTD.: BUSINESS OVERVIEW
    • FIGURE 38 COMPANY SNAPSHOT: TORAY MEDICAL CO., LTD.
    • TABLE 110 TORAY MEDICAL CO., LTD.: PRODUCT OFFERINGS
    • 11.1.8 NIPRO CORPORATION
    • TABLE 111 NIPRO CORPORATION: BUSINESS OVERVIEW
    • FIGURE 39 COMPANY SNAPSHOT: NIPRO CORPORATION
    • TABLE 112 NIPRO CORPORATION: PRODUCT OFFERINGS
    • 11.1.9 INFOMED SA
    • TABLE 113 INFOMED SA: BUSINESS OVERVIEW
    • TABLE 114 INFOMED SA: PRODUCT OFFERINGS
    • 11.1.10 MEDICA SPA
    • TABLE 115 MEDICA SPA: BUSINESS OVERVIEW
      • 11.1.10.2 Products offered
    • TABLE 116 MEDICA SPA: PRODUCT OFFERINGS
    • 11.1.11 MEDITES PHARMA SPOL. S.R.O
    • TABLE 117 MEDITES PHARMA SPOL. S.R.O: BUSINESS OVERVIEW
    • TABLE 118 MEDITES PHARMA SPOL. S.R.O: PRODUCT OFFERINGS
    • 11.1.12 MEDICAL COMPONENTS, INC.
    • TABLE 119 MEDICAL COMPONENTS, INC.: BUSINESS OVERVIEW
    • TABLE 120 MEDICAL COMPONENTS, INC.: PRODUCT OFFERINGS
    • 11.1.13 SWS HEMODIALYSIS CARE CO. LTD.
    • TABLE 121 SWS HEMODIALYSIS CARE CO. LTD.: BUSINESS OVERVIEW
    • TABLE 122 SWS HEMODIALYSIS CARE CO. LTD.: PRODUCT OFFERINGS
    • 11.1.14 NINGBO TIANYI MEDICAL DEVICES CO., LTD.
    • TABLE 123 NINGBO TIANYI MEDICAL DEVICES CO., LTD.: BUSINESS OVERVIEW
    • TABLE 124 NINGBO TIANYI MEDICAL DEVICES CO., LTD.: PRODUCT OFFERINGS
    • 11.1.15 ANJUE MEDICAL EQUIPMENT CO., LTD.
    • TABLE 125 ANJUE MEDICAL EQUIPMENT CO., LTD.: BUSINESS OVERVIEW
    • TABLE 126 ANJUE MEDICAL EQUIPMENT CO., LTD.: PRODUCT OFFERINGS
  • 11.2 EMERGING PLAYERS
    • 11.2.1 KIMAL
    • 11.2.2 JIANGXI SANXIN MEDTEC CO., LTD.
    • 11.2.3 ALLMED MEDICAL PRODUCTS CO., LTD.
    • 11.2.4 DIALCO MEDICAL INC.
    • 11.2.5 BROWNDOVE HEALTHCARE PVT. LTD.
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 AVAILABLE CUSTOMIZATIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS